Outside experts say, however, that the choice of control group in the trial may limit the relevance to clinical practice.
HealthDay on MSN7h
Newer Drug Could Be Advance Against Tough-to-Treat Breast CancersAn experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast ...
The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival ...
Pfizer (PFE) and Alliance Foundation Trials announced results from the Phase 3 PATINA trial demonstrating that the addition ...
Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.
IN8bio, Inc., a clinical-stage biopharmaceutical company focusing on innovative gamma-delta T cell therapies, recently shared updated data on December 10, 2024. This data demonstrated sustained ...
The FDA issued a second, expanded recall of duloxetine after higher than acceptable levels of a cancer-causing chemical were ...
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $12.00.Pick ...
Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos ...
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...
AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback